Emmaus Life Sciences to Present Phase 3 Sickle Cell Disease Clinical Trial Data
Oral Presentations at the 9th Annual Sickle Cell Disease Research and
and 38th National Sickle Cell Disease Scientific Meeting
TORRANCE, Calif.--(BUSINESS WIRE)-- Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases today announced that data from the Company’s Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting. The conference is being held April 10-13, 2015 in Hollywood, FL at the Westin Diplomat.
“We look forward to sharing the positive safety and efficacy results of our Phase 3 trial of PGLG in treating sickle cell patients with leading experts in sickle cell research, treatment and advocacy,” said Dr. Niihara.
The data from the prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center clinical trial that enrolled 230 adult and pediatric patients as young as five years of age, across 31 U.S. sites will be presented. Clinical benefits of the PGLG treatment, as reported in an abstract submitted to the Journal of Sickle Cell Disease and Hemoglobinopathies, include a reduction in the median frequency of sickle cell crisis, a lower median frequency of hospitalizations, a reduction in median cumulative hospital days, and fewer cases of acute chest syndrome, with a well-tolerated safety profile.
Oral Presentation Details:
|Investigational Drug Symposium - Sunday, April 12, 2015|
|Plenary Session II - Monday, April 13, 2015 at 8:00 a.m. EST|
About Emmaus Life Sciences
Emmaus Life Sciences is dedicated to the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The Company’s research on sickle cell disease and sickle beta-0 thalassemia was initiated by Dr. Niihara at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. The therapy has Orphan Drug designation in the U.S. and Europe and Fast Track designation from the FDA.
For more information, please visit www.emmauslifesciences.com.
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development, potential commercialization of pharmaceutical products, including the preparation and submission of a new drug application. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Additional risks and uncertainties are described in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2014 and Quarterly Reports on Form 10-Q. Emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
Source: Emmaus Life Sciences, Inc.
Released March 31, 2015